Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04566003
Other study ID # GN42801
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date October 26, 2020
Est. completion date June 27, 2023

Study information

Verified date July 2023
Source Genentech, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study aims to compare tau targeted radiotracers [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in subjects with normal cognition or prodromal to moderate Alzheimer's disease (AD).


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date June 27, 2023
Est. primary completion date June 27, 2023
Accepts healthy volunteers No
Gender All
Age group 50 Years to 90 Years
Eligibility Inclusion Criteria - Cognitively normal subjects aged 65 to 90 years and prodromal to mild AD subjects aged 50 to 90 years, inclusive at the time of screening. - Prodromal to moderate AD subjects: Meet the National Institute on Aging - Alzheimer's Association (NIA-AA) core clinical criteria for mild cognitive impairment (MCI) due to AD, probable AD dementia or AD dementia - Have a Clinical Dementia Rating (CDR) score of 0 (cognitively normal) or 0.5 (prodromal to moderate AD) at screening - Have an Mini-Mental State Examination (MMSE) score 10-30 inclusive - Have Aß PET imaging demonstrating Aß binding based on qualitative visual read at screening or using an acceptable historical PET scan (cognitively normal subjects will be assessed with Aß PET at screening but will not be required to demonstrate Aß binding). - A brain MRI consistent with normal cognition or that supports a diagnosis of prodromal to moderate AD, with no evidence of other significant neurologic pathology. A previously acquired research MRI within the last 12 months may be used if deemed acceptable by the investigator and no significant clinically relevant changes have occurred since the prior MRI was obtained - The subject has an appropriate study partner capable of participating in CDR assessment and, if necessary, of accompanying the subject - For cognitively normal subjects only: History of at least one first degree relative with diagnosis of Alzheimer's disease (self-reported by the potential subject and/or confirmed by the study partner). Exclusion Criteria - Current or prior history of any alcohol or drug abuse within the last 2 years - Prior participation in other research protocols or clinical care in the last year in addition to the radiation exposure expected from participation in this clinical study, such that radiation exposure exceeds the effective dose of 50 millisievert (mSv), which would be above the acceptable annual limit established by the US Federal Guidelines - Evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, alternative neurological, immunodeficiency, pulmonary, or other disorder or disease - MRI evidence of cerebrovascular disease, infectious disease, space-occupying lesions, normal pressure hydrocephalus, or other central nervous system (CNS) disease - Implants that have not been certified for MRI or history of claustrophobia in MRI, unless an acceptable previously acquired research MRI is available

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
[18F]GTP1
Participants will receive a bolus IV of approximately 7mCi of [18F]GTP1 radiotracer.
[18F]PI-2620
Participants will receive a bolus IV of approximately 5mCi of [18F]PI-2620 radiotracer.
[18F]MK-6240
Participants will receive a bolus IV of approximately 5mCi of [18F]MK-6240 radiotracer.

Locations

Country Name City State
United States Invicro, a Konica Minolta company New Haven Connecticut

Sponsors (1)

Lead Sponsor Collaborator
Genentech, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants with Adverse Events (AEs) Up to approximately 4 days after administration of each radiotracer
Primary Brain tau burden as measured by [18F]PI-2620 - PET Approximately 1 hour after injection of [18F]PI-2620
Primary Brain tau burden as measured by [18F]GTP1 - PET Approximately 1 hour after injection of [18F]PI-2620
Primary Brain tau burden as measured by [18F]MK-6240 - PET Approximately 1 hour after injection of [18F]MK-6240
See also
  Status Clinical Trial Phase
Recruiting NCT03030586 - ADDIA Proof-of-Performance Clinical Study
Withdrawn NCT04055532 - Biomarkers in Neurodegenerative Diseases
Recruiting NCT05395624 - Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers Phase 1/Phase 2
Completed NCT03518073 - A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease Phase 2